Veracyte, Inc. (VCYT)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
48.17-8.21 (-14.56%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 53.57 |
| Open | 54.41 |
| Bid | 52.55 x 1000 |
| Ask | 60.08 x 1200 |
| Day's Range | 54.41 - 56.83 |
| 52 Week Range | 21.08 - 86.03 |
| Volume | 1,480,293 |
| Avg. Volume | 1,078,986 |
| Market Cap | 3.227B |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings Date | May 04, 2021 - May 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 84.83 |
- Business Wire
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
- Business Wire
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
The first patient has been enrolled and randomized in Acerta Pharma’s ESCALADE trial, which is using Veracyte's LymphMark lymphoma subtyping test.
- Motley Fool
3 Cancer Diagnostic Monster Stocks on Sale
These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.
© 2021 Verizon Media. All rights reserved.
